Cyprotex

Cyprotex is a leading provider of preclinical ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) services, dedicated to supporting the pharmaceutical and biotechnology industries. Established in the UK, the company has built a reputation for delivering high-quality data that informs drug development processes.

With a focus on innovation, Cyprotex employs advanced technologies and methodologies to assess the pharmacokinetics and safety profiles of new compounds. Their comprehensive suite of services includes in vitro and in vivo testing, predictive modelling, and regulatory support, ensuring clients receive robust and reliable data.

The company prides itself on its commitment to scientific excellence and customer satisfaction. By collaborating closely with clients, Cyprotex tailors its services to meet specific project needs, helping to accelerate drug development timelines.

Core Services:

• ADMET Testing: Comprehensive assessments of absorption, distribution, metabolism, excretion, and toxicity.
• Predictive Modelling: Utilising cutting-edge software to predict pharmacokinetic properties.
• Regulatory Support: Guidance through the complexities of regulatory submissions and compliance.

Cyprotex’s state-of-the-art facilities are equipped with the latest technology, enabling them to conduct a wide range of assays efficiently. The team consists of highly skilled scientists and industry experts who are passionate about advancing drug discovery.

As a forward-thinking company, Cyprotex is committed to sustainability and ethical practices in all its operations. They strive to reduce environmental impact while providing essential services to their clients.

In summary, Cyprotex stands at the forefront of drug development support, offering unparalleled expertise and innovative solutions to help bring new therapies to market faster and more safely.